HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Treatment of anterior segment fibrinous reactions and hemorrhage with intracameral low dose rt-PA: clinical study and review of the literature].

AbstractPURPOSE:
to evaluate the efficacy and the safety of low dose intraocular tissue plasminogen activator (rt-PA) in the treatment of traumatic hyphema and postoperative fibrinous membrane.
METHODS:
Six microg to 10 microg of rt-PA was injected into the anterior chamber to treat severe fibrinous postoperative membranes and total traumatic hyphemae.
RESULTS:
Thirteen eyes of 13 patients were treated. Four cases of traumatic hyphema and 9 cases of fibrinous membranes were included. Complete fibrinolysis within 24 hours was observed in 4 cases (30.8%). A partial success was noted in 7 eyes (53.8%). No beneficial effect was observed in two cases of traumatic hyphema associated with intravitreal hemorrhage after penetrating trauma. No side effect attributable to rt-PA occurred.
CONCLUSION:
Low dose intraocular rt-PA appears to be safe and effective in the treatment of postoperative fibrinous membrane and endocular hemorrhage limited to the anterior chamber.
AuthorsJ F Le Rouic, F Behar-Cohen, M H Nghiem, G Renard, D Chauvaud
JournalJournal francais d'ophtalmologie (J Fr Ophtalmol) Vol. 23 Issue 10 Pg. 977-83 (Dec 2000) ISSN: 0181-5512 [Print] France
Vernacular TitleIntérêt des faibles doses de rt-PA dans les syndromes inflammatoires et hémorragiques du segment antérieur: étude clinique et revue de la littérature.
PMID11139689 (Publication Type: Clinical Trial, Journal Article, Review)
Chemical References
  • Fibrinolytic Agents
  • Recombinant Proteins
  • Fibrin
  • Tissue Plasminogen Activator
Topics
  • Adolescent
  • Adult
  • Aged
  • Child
  • Eye Injuries (drug therapy)
  • Female
  • Fibrin (metabolism)
  • Fibrinolytic Agents (therapeutic use)
  • Humans
  • Hyphema (drug therapy)
  • Inflammation (drug therapy, etiology)
  • Male
  • Middle Aged
  • Ophthalmologic Surgical Procedures
  • Postoperative Complications (drug therapy)
  • Recombinant Proteins (therapeutic use)
  • Tissue Plasminogen Activator (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: